Association of HLA-DRA and IL2RA Polymorphisms with the Severity and Relapses Rate of Multiple Sclerosis in an Iranian Population

Heat shock protein 70 gene polymorphisms in Iranian patients with Multiple sclerosis

Genetic factors are effective reagents in susceptibility to multiple sclerosis (MS). Previous studies have shown the relationship between heat shock protein (HSP) gene polymorphisms. So, HSP70 single nucleotide polymorphisms (SNPs) were evaluated as MS risk factors. Here, DNA genotyping was done for HSP70 gene polymorphisms, including HSP70-1 +190 G>C, HSP70-1 -110 A>C, HSP70-1 +438 A>C, and HSP70-hom +2437 A>G in two groups including Iranian MS patients and controls. A standard phenol/chloroform method isolated DNA samples from peripheral blood. Sequence-specific amplification (SSP) polymerase chain reaction (PCR) was used for genotyping polymorphisms. Overall, 76 (35.80%) MS patients and 136 (65.10%) controls were studied with an age mean of 36.0 ± 8.0 years. Female/male was significantly higher in patients than in controls (4.43 vs. 0.10, P < 0.001). The average age was significantly lower in patients (P < 0.001). The most common clinical feature was relapsing-remitting (RR) MS; more than half of the population was Fars. Results showed that genotypes of HSP70-hom +2437 C>T had a significant relation with MS (OR = 2.0, 95% CI = 1.0-5.0, P = 0.03) and the same applies to HSP70-1 -110 A>C (OR = 0.0, 95% CI = 0.0-1.0, P < 0.001). Allele and genotype frequency of two other HSP70 SNPs (HSP70-1 +190 G>C, HSP70-1 +438 A>C) showed no significant differences between patients and controls. HSP70-hom +2437 C>T and HSP70-1 -110 A>C can be considered as risk factors for MS in our population. However, other HSP SNPs should be studied in a larger population in the future.

Correlation of -475 IL-2 Promoter Gene Polymorphisms and the Levels of Serum IL-2 on the Risk of Multiple Sclerosis

BACKGROUND

The aim of present study is to asset the IL-2 promoter gene (SNP -475) as a candidate gene for multiple sclerosis (MS) susceptibility.

METHODS

This study included 70 patients with relapsing - remitting multiple sclerosis (RRMS) and 50 healthy controls. Following the extraction of genomic DNA from peripheral blood, frequency of genotypes and alleles of SNP -475 was calculated using Restriction fragment length polymorphism-polymer chain reaction (RFLP-PCR) and then the results were analyzed statistically.

RESULTS

The results revealed the unusual ratio for the heterozygous (AT) was 1.6972 indicating that heterozygous patients were at higher risk of multiple sclerosis than wild homozygous (AA), and homomutant (TT). The results show protective role for - 475 IL-2 promoter among individuals with multiple sclerosis, (O.R: 0.4872; C.I. 95%: 0.1617- 1.4680) and (O.R: 0.9275; C.I. 95%: 0.2476 - 3.4745) for both AA and TT genotypes, respectively.

CONCLUSION

Our results showed that in this population of Iraqi patients, the AT genotype / A allele of -475 IL-2 promoter gene SNP may include attributed factors for MS predisposition.

A CB2 Receptor Agonist Reduces the Production of Inflammatory Mediators and Improves Locomotor Activity in Experimental Autoimmune Encephalomyelitis

Background

Cannabinoids (CBs) have been found to regulate the immune system, affect innate and adaptive immune responses, and reduce inflammatory reactions. This study assessed the therapeutic effects of GW-405833 synthetic CB2 agonist on inflammatory factors as well as locomotor activity in experimental autoimmune encephalomyelitis (EAE).

Methods

In this experimental study, 48 adult male C57BL/6 mice were randomly and equally assigned to eight groups. By injecting 250 mg of MOG35-55 peptide, EAE was induced. Every other day for 17 days after EAE onset, EAE-afflicted mice in groups 1-3 received an intraperitoneal injection of GW-405833 at a dose of 3, 10, and 30 mg/kg, respectively. Clinical status and locomotor activity, measured using the beam walking assay, were assessed every other day during the first 17 days after EAE onset. Mice were euthanized in day 17th of treatment and the serum levels of the IL-1β, IL-12, CRP, and TNF-α proinflammatory cytokines as well as IL-4 and TGF-β anti-inflammatory cytokines were measured by ELISA method.

Results

Clinical manifestations of EAE in groups 2 and 3 were significantly milder than group 4 and locomotor activity in groups 1-3 was significantly better than group 4 in days 5-17 (p< 0.05). GW-405833 also significantly decreased the levels of IL-12, TNF-α, and CRP and significantly increased the levels of IL-4 and TGF-β but had no significant effects on the level of IL-1β. GW-405833 was not associated with significant side effects.

Conclusion

The CB2 receptor agonist GW-405833, improves clinical conditions and reduces inflammation in mice with EAE.